BioSpace News Archive

Exact Imaging (www.exactimaging.com), the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, and its ExactVu micro-ultrasound system will be featured prominently at the 114th Annual Meeting of the AUA (American Urological Association)

Contextual Genomics announced today that Sue Paish will become the new Chair of the Company’s Board of Directors effective May 1, 2019.

SentreHEART, Inc., announced it has received CE Mark for the LARIAT-RS™ 50mm as well as expanded labeling for the LARIAT-RS for left atrial appendage (LAA) exclusion.

QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) announced today that it had posted its 2018 Annual Report on its website at http://financialreport.qiagen.com.

Caris Life Sciences®, a leading innovator in molecular science focused on precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the company’s MI Transcriptome™ companion diagnostic (CDx) test.

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2019.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the New England Journal of Medicine (NEJM) published positive data from the Phase 3 PREVENT study of SOLIRIS® (eculizumab), a first-in-class complement inhibitor, in adult patients with anti-aquaporin-4 (AQP4) auto antibody-positive neuromyelitis optica spectrum disorder (NMOSD)

Each year, St. Mary’s General Hospital Foundation hosts RedDAY to raise awareness of the serious risk of heart disease in women, rallying people, workplaces and community leaders from across Waterloo Region to mark the day by wearing red and sharing images on social media with the hashtag #RedDayFriday.

Hi-Tech Pharmaceuticals sued the FDA May 2nd, 2019 in Federal Court- Case 1:19-cv-01268, claiming the agency bypassed standard rule-making procedures in favor of a campaign of intimidation to try to force companies to destroy their products containing 2-Aminoisopheptane, or DMHA

Canopy Rivers Inc. (“Canopy Rivers” or the “Company”) (TSXV: RIV) (OTC: CNPOF) congratulates its portfolio company TerrAscend Corp. (“TerrAscend”) (CSE: TER) (OTCQX: TRSSF) on its announcement yesterday that its facility in Mississauga, Ontario, Canada has been issued a Good Manufacturing Practice (“GMP”) certificate in accordance with the rules governing medicinal products in the European Union (